Pimozide
As of the edition of 20 October 2026, Pimozide is a small molecule: marketed, first approved in 1971 (ES); acts on DRD1, DRD2 and DRD3 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Orap
- First approved
- 1 November 1971 (ES)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Teva; 4 holders in all
- Registered trials
- 7, 1 stopped early
- Disease areas
- Mental health; Nervous system; Ear, nose and throat; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 7 |